Jones Trading Reiterates Buy Rating for ProQR Therapeutics
Jones Trading maintains a buy rating for ProQR Therapeutics with a $10 price target, a 446.45% upside from the current price.
Key Points
- Jones Trading reiterated its buy rating on ProQR Therapeutics with a $10 price target on June 26, 2026.
- Jones Trading's $10 price target implies 446.45% upside from ProQR Therapeutics N.V.'s ($PRQR) current $1.83 share price.
- ProQR Therapeutics, trading at $1.56, has a market cap of $161.2 million and a 52-week range of $1.33 to $3.10.
- Insider Hinsch Gylvin Lykke bought 14,495 shares on June 2, 2026, while major funds like Aberdeen Group increased their stakes.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Jones Trading reiterated its buy rating on ProQR Therapeutics N.V. (NasdaqCM: PRQR) on June 26, 2026. Analyst Catherine Novack set a price target of $10, suggesting significant upside from the current trading price of $1.56.
Jones Trading vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in ProQR Therapeutics
Several institutional investors also showed interest in ProQR Therapeutics. Aberdeen Group PLC increased its holdings by 366,289 shares, resulting in a total of 3,316,965 shares valued at approximately $5.37 million, marking a 12.4% increase. Privium Fund Management B.V. added 109,387 shares, bringing its total to 5,467,149 shares worth about $8.86 million, a 2.0% increase. Meanwhile, SIO Capital Management, LLC reduced its stake by 209,466 shares, ending with 1,954,715 shares valued at around $3.17 million, representing a 9.7% decrease.
ProQR Therapeutics N.V. Stock Down 20.1%
Shares of ProQR Therapeutics traded at $1.56 on Saturday. The company has a market cap of $161.2 million and a beta of 0.061, indicating low volatility. The stock's 52-week range spans from $1.33 to $3.10, with a 50-day moving average of $1.60 and a 200-day moving average of $1.90. ProQR's financial health is supported by a current ratio of 2.48 and a quick ratio of 2.39, though it carries a debt-to-equity ratio of 41.85.
$PRQR price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
ProQR Therapeutics reported revenue of $13.64 million, though it saw a decline with a revenue growth rate of -57.1%. The company is not profitable, with a net margin of 0.0% and a return on equity of -78.1%. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at ProQR Therapeutics N.V.
On June 2, 2026, an insider named Hinsch Gylvin Lykke purchased 14,495 shares of ProQR Therapeutics. This transaction was not part of a pre-planned trading program.
Analysts Set New Price Targets
On June 26, 2026, Chardan Capital also maintained its buy rating with a price target of $3.00. The consensus among analysts is a buy rating, with a mean target price of $8.88 based on eight opinions.
About ProQR Therapeutics
ProQR Therapeutics N.V. is a biotechnology company based in Leiden, Netherlands. It focuses on developing RNA editing technology through its Axiomer platform to treat genetic disorders. The company's leading products target various health conditions, including cholestatic diseases and Rett syndrome. Under the leadership of CEO Daniel Anton de Boer, ProQR collaborates with Eli Lilly to advance treatments for genetic disorders in the liver and nervous system.
Bottom Line
Jones Trading's reiteration of a buy rating for ProQR Therapeutics reflects optimism in the company's potential, despite its current low price. Investors keep a close watch on such analyst ratings, though it's important to remember that these insights are based on past performance and market conditions. ProQR's recent insider activity and institutional interest suggest that stakeholders are paying attention to its future prospects.
Get ProQR Therapeutics N.V. alerts
New 13F filings, insider trades, and analyst moves on $PRQR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.